Table 4.
Results by study group | Comparison between the groups‡ | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control (follow-up years: 296·7) | 10 g LNS/d (follow-up years: 294·9) | 20 g LNS/d (follow-up years: 595·8) | 40 g LNS/d (follow-up years: 601·9) | 10 g LNS/d v. control | 20 g LNS/d v. control | 40 g LNS/d v. control | ||||||||
Variable | Total visits | Incidence | Total visits | Incidence | Total visits | Incidence | Total visits | Incidence | IRR | 95 % CI | IRR | 95 % CI | IRR | 95 % CI |
All non-scheduled visits | 1412 | 4·8 | 1417 | 4·8 | 2988 | 5·0 | 3217 | 5·3 | 1·02 | 0·89, 1·18 | 1·05 | 0·93, 1·19 | 1·13 | 1·00, 1·27* |
Gastroenteritis | 163 | 0·5 | 159 | 0·5 | 298 | 0·5 | 324 | 0·5 | 0·98 | 0·76, 1·27 | 0·91 | 0·73, 1·14 | 0·98 | 0·79, 1·22 |
ARI | 454 | 1·5 | 446 | 1·5 | 938 | 1·6 | 1041 | 1·7 | 1·02 | 0·84, 1·22 | 1·04 | 0·88, 1·22 | 1·14 | 0·98, 1·34 |
Clinical malaria | 185 | 0·6 | 174 | 0·6 | 418 | 0·7 | 409 | 0·7 | 0·94 | 0·74, 1·20 | 1·12 | 0·92, 1·37 | 1·08 | 0·89, 1·33 |
Confirmed malaria§ | 385 | 1·3 | 418 | 1·4 | 834 | 1·4 | 941 | 1·6 | 1·10 | 0·88, 1·37 | 1·08 | 0·89, 1·31 | 1·21 | 1·00, 1·46* |
Total malaria | 570 | 1·9 | 592 | 2·0 | 1252 | 2·1 | 1350 | 2·2 | 1·04 | 0·87, 1·25 | 1·09 | 0·93, 1·28 | 1·16 | 1·00, 1·36* |
Other diseases|| | 274 | 0·9 | 244 | 0·8 | 581 | 1·0 | 627 | 1·0 | 0·89 | 0·71, 1·12 | 1·05 | 0·87, 1·27 | 1·13 | 0·93, 1·36 |
LNS, lipid-based nutrient supplement; IRR, incidence rate ratio; ARI, acute respiratory infection.
Statistically significant results.
Incidence=number of cases/child per year of follow-up.
Groups were compared using negative binomial regression.
Measured by rapid diagnostic test (RDT) for malaria parasites based on histidine-rich protein (HRP-II).
Other diseases=sepsis, measles, anaemia, etc.